A Case Report of the Second de Novo Acute Myeloid Leukemia (AML) Following Allogeneic Stem Cell Transplantation in a Patient with the First AML.
10.3904/kjim.2010.25.1.110
- Author:
Byung Sik CHO
1
;
Hee Je KIM
;
Ki Sung EOM
;
Jong Wook LEE
;
Woo Sung MIN
;
Chun Choo KIM
Author Information
1. Division of Hematology, Department of Internal Medicine, Catholic Blood and Marrow Transplantation Center, The Catholic University of Korea School of Medicine, Seoul, Korea. cumckim@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Leukemia, myeloid, acute;
Hematopoietic stem cell transplantation
- MeSH:
Adult;
Cytogenetic Analysis;
Hematopoietic Stem Cell Transplantation/*adverse effects;
Histocompatibility Testing;
Humans;
Leukemia, Myeloid, Acute/*etiology/pathology/*therapy;
Male;
Neoplasms, Second Primary/*etiology/pathology;
Transplantation, Homologous
- From:The Korean Journal of Internal Medicine
2010;25(1):110-113
- CountryRepublic of Korea
- Language:English
-
Abstract:
Secondary leukemia occurring after hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) is rare. Secondary AML usually follows autologous and not allogeneic transplants. When a new leukemia develops in a patient successfully treated with an allogeneic HSCT, the possibility of a de novo or secondary leukemia from either the donor or recipient should be considered. We present a case initially diagnosed as de novo AML without a cytogenetic abnormality. The patient was successfully treated with an HLA-matched sibling allogeneic HSCT. However, more than six years later, AML developed again and was associated with new complex cytogenetic abnormalities. After a second HSCT, the patient has been followed without serious complications. Considering the allogeneic setting, the newly developed cytogenetic abnormalities, a relatively long latent period, and the good clinical course after the second allogeneic HSCT, this case might represent a second de novo AML following successful treatment of the first AML.
